Solasia Pharma K.K. announced that WEP Clinical LTD (a UK- & US-based company, hereinafter "WEP"), have commenced a Named Patient Program (NPP) for DARVIAS® Injection 135 mg, anti-tumor agents /Organoarsenic compound [generic name: darinaparsin] (hereinafter " DARVIAS® "), a treatment for relapsed or refractory Peripheral T-Cell Lymphoma (hereinafter "PTCL"). DARVIAS® is an anti-cancer agent with a novel mechanism of action, which was approved and launched in Japan in 2022 for relapsed or refractory PTCL. The NPP is designed to ensure that physicians in Europe and other regions around the world, where DARVIAS® is not commercially available, can request DARVIAS® on behalf of individual patients who need a new treatment option in PTCL.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26 JPY | +4.00% | +4.00% | -42.22% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.22% | 30.07M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- 4597 Stock
- News Solasia Pharma K.K.
- Solasia Partners with WEP Clinical to Supply Darvias [Darvias Injection 135Mg] Under a Named Patient Program